New method finds compounds that bind and inhibit individual members of a family of key regulatory proteins, called cyclophilins, that have been difficult to target selectively.
Researchers have boosted the efficiency of prime editing, a highly versatile CRISPR-based gene editing technology, and used the improved system to correct disease mutations in cells.
By engineering proteins called proteases to find new targets with high selectivity, researchers mark a critical advance toward potential new treatments for a wide range of conditions